 |
SV Life Sciences Fund IIISVLSF III closed in 2003 with total commitments of $393 million (plus $8 million of co-investments committed by partners and individuals affiliated with SVLS). As at 31 March 2010 the Fund had invested $374 million in 39 portfolio companies. To go to individual portfolio companies websites please click on company logo. Biotechnology / Biopharmaceuticals
Alantos Pharmaceuticals: US - Exited
First investment: 2003 - Early Stage Alantos was a chemistry-driven company seeking to discover and develop drugs targeted at osteoarthritis and inflammatory processes. The company attempts to fast follow others to reduce risk. 
Alba Therapeutics: US
First investment: 2005 - Early Stage Alba is based in Baltimore, MD, is focused on the development and commercialization of pharmaceuticals for the treatment of inflammatory and immune mediated diseases. Alba’s technology provides the ability to transiently open or close internal barriers such as the intestinal mucosa. Alba is applying its technology to develop treatments for celiac disease and other autoimmune conditions. 
Alinea: US
First investment: 2005 - Expansion 
Archemix: US
First investment: 2002 - Early Stage Archemix is based in Cambridge, MA, developing nucleic acid aptamers for therapeutic indications, building on a broad IP portfolio acquired from Gilead/Nexstar. 
Avera Pharmaceuticals: US - Exited
First investment: 2004 - Early Stage Avera is based in San Diego, CA and focused on the development of small molecule drugs for the treatment of diseases affecting the central nervous system (CNS). Key programs are Alzheimer’s disease, schizophrenia associated cognition deficits, IBS, and OAB, and developing an ultra-short acting anaesthesia compound. 
Celldex/Lorantis: UK - Exited
First investment SVLSF II: 2001 - Seed First investment SVLSF III: 2003 - Seed Celldex merged with the quoted company Avant Immunotherapeutics (ticker:'AVAN') in March 2008. Celldex, formerly a wholly owned subsidiary of Medarex Inc., merged with Lorantis Ltd in 2005. Celldex pursues immunological approaches to the treatment of cancers, infectious disease and immunological disorders. 
Delenex Therapeutics: Switzerland
First investment SVLSF III: 2009 - Early Stage Delenex is a spin out from ESBATech, an investment that was divested in 2009. The business focuses on research and development in to its antibody fragments for delivering next generation Therapeutics application. 
Dynogen Pharmaceuticals: US - Exited
First investment: 2004 - Early Stage Dynogen is a neuroscience-based company focused on genito-urinary (GU) and gastro-intestinal (GI) disorders. The company is using its knowledge of neurology and GU/GI disorders to build a pipeline of clinical candidates. 
ESBATech: Switzerland
First investment: 2006 - Early Stage ESBATech is a preclinical stage drug discovery company that intends to refocus the business to build a world class Ophthalmology company on the back of an attractive, proprietary antibody fragment platform which can deliver uniquely stable, soluble and monomeric fragments and compelling data on penetration of these fragments into the eye following topical treatment. 
GlycoFi: US - Exited
First investment: 2002 - Start Up GlycoFi was a production and engineering of therapeutics proteins. 
Ikano: US
First investment: 2006 - Early Stage Intranasal Therapeutics, Inc. (“ITI”) based in Montvale, NJ, is a specialty pharmaceutical company focused on developing innovative, nasally delivered pharmaceutical products with a particular focus on drugs treating pain and CNS-related disorders for which there is proven, unsatisfied consumer demand. The company will be developing new formulations of already marketed drugs and will pursue U.S. regulatory approval using the FDA 505(b)2* regulations. Formerly known as Intranasal Therapeutics. 
Lux Biosciences: US
First investment: 2006 - Seed Lux is developing drugs for ophthalmic diseases. Their lead products are a Cyclosporin implant for corneal transplant,and ISA247 for uveitis. Both programs are in Phase III development. Additional programs are an ISA247 implant for dry eye and Age-related Macular Degeneration. 
Mpex Pharmaceuticals: US
First investment: 2005 - Early Stage Mpex based in San Diego, CA, is focused on the discovery and development of new-antibacterial drugs that meet the growing clinical need created by multi-drug resistant bacteria. Mpex has identified several approaches to increase the effectiveness of existing antibiotics and decrease the incidence of drug resistance to these antibiotics. Mpex’s first product will be an inhaled antibiotic for serious lung infections. 
Neurotech: US
First investment: 2006 - Early Stage Neurotech based in Lincoln, RI, has developed an encapsulated cell therapy for the delivery of therapeutic proteins in retinal diseases. The first product is ciliary neurothrophic factor (CNTF) for retinitis pigmentosa and age-related macular degeneration (geographic atrophy). 
PowderMed: UK - Exited
First investment: 2004 - Early Stage PowderMed developed therapeutic DNA vaccines in the areas of chronic viral diseases and cancer. 
Rinat Neuroscience: US - Exited
First investment: 2003 - Early Stage Rinat developed proteins for the treatment of diseases and disorders of the nervous system. 
Sapphire Pharmaceuticals: US - Exited
First investment: 2004 - Early Stage Helsinn is developing small molecule drugs based on the biology of ghrelin,a gut peptide known to stimulate appetite. The lead compound is in Ph II for cancer cachexia; a second compound has completed an initial clinical study and is moving toward Ph II for post-operative ileus. Additional indications are being explored for follow-on compounds. Formerly known as Rejuvenon. 
Sutro Biopharma, Inc.: US
First investment: 2006 - Early Stage Sutro Biopharma's mission is to enable the production of low-cost, high quality rapidly developed protein pharmaceuticals and innovative vaccines that cannot be manufactured by existing technologies. Previously known as Fundamental Applied Biology’s (FAB). 
| |
